Adial Pharmaceuticals, Inc.

1001 Research Park Blvd., Suite 100

Charlottesville, Virginia 22911

 

February 19, 2019

 

VIA EDGAR

 

United States Securities

    and Exchange Commission
Division of Corporation Finance

100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Todd Schiffman

 

  Re: Adial Pharmaceuticals, Inc.
   

Registration Statement on Form S-1, as amended

File No: 333-229615

 

Ladies and Gentlemen:

 

Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-229615), be accelerated by the U.S. Securities and Exchange Commission to Wednesday, February 20, 2019, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.

 

The Registrant hereby authorizes its legal counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (516) 457-4238 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

 

  Very truly yours,
   
  ADIAL PHARMACEUTICALS, INC.
   
  By: /s/ Willian B. Stilley III
  Name: William B. Stilley III
  Title: Chief Executive Officer
     

  

cc: Leslie Marlow, Esq., Gracin & Marlow, LLP